Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana

Clinical and Applied Thrombosis/Hemostasis

Volumn 24, Issue 4, 2018, Pages 596-601

  Mwita, Julius C ^a,b   Francis, Joel M ^c   Oyekunle, Anthony A ^a,b   Gaenamong, Marea ^b   Goepamang, Monkgogi ^b   Magafu, Mgaywa G M D ^d  

^a UNIVERSITY OF BOTSWANA   (Botswana)

^b PRINCESS MARINA HOSPITAL   (Botswana)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

anticoagulation control; Botswana; quality; warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ADULT; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PROPHYLAXIS; PROSTHETIC VALVE THROMBOSIS; PULMONARY HYPERTENSION; TERTIARY CARE CENTER; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; BOTSWANA; HEALTH CARE QUALITY; RISK FACTOR; STANDARDS;

ADULT; ANTICOAGULANTS; BOTSWANA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF HEALTH CARE; RISK FACTORS; TERTIARY CARE CENTERS; WARFARIN;

EID: 85042119180     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029617747413     Document Type: Article

References (37)

1. Hsu JC, Maddox TM, Kennedy KF. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1(1):55–62.
2. Lip GY, Laroche C, Dan GA. ‘Real-World’ antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am J Med. 2014;127(6):519–529.e1.
3. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol. 2005;45(2):127–132.
4. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis. 2008;25(1):61–66.
5. Hirsh J, Fuster V, Ansell J, Halperin JL. American heart association/American college of cardiology foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41(9):1633–1652.
6. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 1996; 348(9028):633–638.
7. Mearns ES, White CM, Kohn CG. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.
8. Rosendaal F, Cannegieter S, Van Der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239.
9. Connolly SJ, Pogue J, Eikelboom J. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–2037.
10. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thrombo Res. 2009;124(1):37–41.
11. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155–1166.
12. Sarawate C, Sikirica MV, Willey VJ, Bullano MF, Hauch O. Monitoring anticoagulation in atrial fibrillation. J Thromb Thrombolysis. 2006;21(2):191–198.
13. Haas S, ten Cate H, Accetta G. Quality of vitamin k antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PloS One. 2016;11(10):e0164076.
14. Singer DE, Hellkamp AS, Piccini JP. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the rocket AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067.
15. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717–719.
16. Limdi NA, Arnett DK, Goldstein JA. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans. Pharmacogenomics. 2008;9(5):511–526.
17. Connolly SJ, Ezekowitz MD, Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
18. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
19. Eikelboom JW, Connolly SJ, Brueckmann M. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–1214.
20. Zühlke L, Engel ME, Karthikeyan G. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the global rheumatic heart disease registry (the REMEDY study). Eur Heart J. 2014;36(18):1115a–1122a.
21. Carapetis JR. Rheumatic heart disease in developing countries. N Engl J Med. 2007;357(5):439–441.
22. Nishimura RA, Otto CM, Bonow RO. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation. 2014;129(23):e57–e185.
23. Manji I, Pastakia S, Do A. Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9(11):2215–2220.
24. Oh S, Goto S, Accetta G. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016;223:543–547.
25. Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMC Health Serv Res. 2017;17(1):389.
26. Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126(4):557–564.
27. Schulman S, Kearon C, Kakkar AK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
28. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100(19):1524–1530.
29. Melamed OC, Horowitz G, Elhayany A, Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care. 2011;17(3):232–237.
30. Bertomeu-González V, Anguita M, Moreno-Arribas J. Quality of anticoagulation with vitamin K antagonists. Clin Cardiol. 2015;38(6):357–364.
31. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci. 2014;348(2):135–138.
32. Temu TM, Lane KA, Shen C. Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya. PLoS One. 2017;12(9):e0185204.
33. Klein S, Slim E, De Kruif M. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med. 2005;63(4):129–136.
34. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest J. 2013;144(5):1555–1563.
35. Bachmann K, Shapiro R, Fulton R, Carroll FT, Sullivan TJ. Smoking and warfarin disposition. Clin Pharmacol Ther. 1979;25(3):309–315.
36. Macedo AF, Bell J, McCarron C. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from clinical practice research datalink. Thromb Res. 2015;136(2):250–260.
37. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121(9):676–683.